Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

Heart failure is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving glycaemic control. In type 2 diabetes (T2D), some SGLT2Is reduce major cardio...

Descripción completa

Detalles Bibliográficos
Autor principal: Tamargo, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2019
Materias:
Heart Failure and Arrhythmias
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523047/
https://www.ncbi.nlm.nih.gov/pubmed/31131034
http://dx.doi.org/10.15420/ecr.2018.34.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523047/
https://www.ncbi.nlm.nih.gov/pubmed/31131034
http://dx.doi.org/10.15420/ecr.2018.34.2

Ejemplares similares